MCID: FML039
MIFTS: 38

Female Reproductive System Disease

Categories: Reproductive diseases

Aliases & Classifications for Female Reproductive System Disease

MalaCards integrated aliases for Female Reproductive System Disease:

Name: Female Reproductive System Disease 12 15 17
Female Reproductive System Disorder 71
Genital Diseases, Female 43

Classifications:



External Ids:

Disease Ontology 12 DOID:229
ICD9CM 34 629.9
MeSH 43 D005831
SNOMED-CT 67 38233001
UMLS 71 C0017411 C0236100

Summaries for Female Reproductive System Disease

Disease Ontology : 12 A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.

MalaCards based summary : Female Reproductive System Disease, also known as female reproductive system disorder, is related to endometriosis and uterine anomalies, and has symptoms including menometrorrhagia, mastodynia and breast engorgement. An important gene associated with Female Reproductive System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs tannic acid and Propofol have been mentioned in the context of this disorder. Affiliated tissues include ovary, cervix and uterus.

Related Diseases for Female Reproductive System Disease

Diseases related to Female Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 endometriosis 33.1 MIR200A MIR199A1 MIR145 MIR143 MIR141
2 uterine anomalies 33.1 MIR9-1 MIR34A MIR31 MIR30A MIR27A MIR214
3 endometriosis of ovary 33.1 MIR9-1 MIR145 MIR141
4 connective tissue disease 31.0 MIR9-1 MIR34A MIR31 MIR30A MIR27A MIR214
5 preterm premature rupture of the membranes 11.2
6 ectopic pregnancy 11.2
7 pelvic inflammatory disease 11.2
8 fallopian tube endometriosis 11.2
9 endosalpingiosis 11.2
10 endometriosis of intestine 11.2
11 endometriosis of pelvic peritoneum 11.2
12 endometriosis in scar of skin 11.2
13 endometriosis of rectovaginal septum and vagina 11.2
14 vaginal disease 11.2
15 hernia of ovary and fallopian tube 11.2
16 prolapse of female genital organ 11.2
17 amenorrhea 11.2
18 masters-allen syndrome 11.2
19 fallopian tube disease 11.2
20 vulvovaginitis 11.2
21 gynatresia 11.2
22 parovarian cyst 11.2
23 bartholin's gland disease 11.2
24 bartholin's duct cyst 11.2
25 ovarian serous carcinoma 10.9 MIR27A MIR214 MIR21 MIR200A MIR199A1 MIR145
26 bone marrow cancer 10.9 MIR9-1 MIR34A MIR30A MIR21 MIR199A1 MIR196A1
27 glucose metabolism disease 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
28 cell type benign neoplasm 10.9 MIR31 MIR21 MIR200A MIR199A1 MIR196A1 MIR17
29 biliary tract disease 10.9 MIR9-1 MIR31 MIR30A MIR200A MIR199A1 MIR196A1
30 bile duct disease 10.9 MIR9-1 MIR31 MIR30A MIR200A MIR199A1 MIR196A1
31 mouth disease 10.9 MIR9-1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
32 ovary epithelial cancer 10.9 MIR30A MIR27A MIR21 MIR200A MIR199A1 MIR196A1
33 malignant ovarian surface epithelial-stromal neoplasm 10.9 MIR30A MIR27A MIR21 MIR200A MIR199A1 MIR196A1
34 central nervous system cancer 10.9 MIR9-1 MIR34A MIR30A MIR214 MIR21 MIR199A1
35 thyroid gland disease 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR193A
36 leukocyte disease 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
37 upper respiratory tract disease 10.9 MIR9-1 MIR31 MIR30A MIR27A MIR21 MIR199A1
38 rectum cancer 10.9 MIR31 MIR214 MIR21 MIR200A MIR196A1 MIR193A
39 immune system disease 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
40 pharynx cancer 10.9 MIR9-1 MIR31 MIR30A MIR27A MIR21 MIR199A1
41 connective tissue cancer 10.9 MIR9-1 MIR31 MIR27A MIR214 MIR21 MIR199A1
42 oral cavity cancer 10.9 MIR9-1 MIR31 MIR30A MIR27A MIR21 MIR199A1
43 tongue disease 10.9 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
44 autosomal genetic disease 10.9 MIR9-1 MIR214 MIR21 MIR199A1 MIR196A1 MIR17
45 central nervous system disease 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
46 mature b-cell neoplasm 10.9 MIR9-1 MIR214 MIR199A1 MIR196A1 MIR17 H2AC18
47 disease of mental health 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 H2AC18
48 bile duct adenocarcinoma 10.9 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR17
49 esophageal disease 10.9 MIR34A MIR30A MIR21 MIR199A1 MIR196A1 MIR193A
50 nasopharyngeal disease 10.9 MIR9-1 MIR31 MIR30A MIR27A MIR21 MIR199A1

Graphical network of the top 20 diseases related to Female Reproductive System Disease:



Diseases related to Female Reproductive System Disease

Symptoms & Phenotypes for Female Reproductive System Disease

UMLS symptoms related to Female Reproductive System Disease:


menometrorrhagia, mastodynia, breast engorgement, nipple discharge, leukorrhea, vaginal pruritus, vaginal odor, vaginal discomfort, pruritus vulvae, genital itching, perineal pain female, genitalia external painful, menopausal symptoms, vaginal pain, burning feeling vagina, mastoscirrhus, discomfort of vulva

Drugs & Therapeutics for Female Reproductive System Disease

Drugs for Female Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
7 Platelet Aggregation Inhibitors Phase 4
8 Anesthetics, General Phase 4
9 Anesthetics, Intravenous Phase 4
10 Anesthetics, Inhalation Phase 4
11 Hormone Antagonists Phase 4
12 Progestins Phase 4
13 Anti-Anxiety Agents Phase 4
14 Tranquilizing Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Hypnotics and Sedatives Phase 4
17 Psychotropic Drugs Phase 4
18 GABA Agents Phase 4
19 Central Nervous System Depressants Phase 4
20 GABA Modulators Phase 4
21
Icodextrin Approved, Investigational Phase 3 337376-15-5
22
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
23
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
24
Ketoprofen Approved, Vet_approved Phase 2, Phase 3 22071-15-4 3825
25
Baclofen Approved Phase 2, Phase 3 1134-47-0 2284
26
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
27
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
28
Gabapentin Approved, Investigational Phase 2, Phase 3 60142-96-3 3446
29
Bismuth subsalicylate Approved, Vet_approved Phase 2, Phase 3 14882-18-9 53629521
30
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
31
Iodine Approved, Investigational Phase 3 7553-56-2 807
32
Povidone Approved Phase 3 9003-39-8
33
Povidone-iodine Approved Phase 3 25655-41-8
34
Bevacizumab Approved, Investigational Phase 3 216974-75-3
35
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
36
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
37
Chitosan Experimental Phase 3 9012-76-4 71853
38 Hypolipidemic Agents Phase 3
39 Anticholesteremic Agents Phase 3
40 Hemostatics Phase 3
41 Chelating Agents Phase 3
42 Coagulants Phase 3
43 Lipid Regulating Agents Phase 3
44 Antimetabolites Phase 3
45 Analgesics, Non-Narcotic Phase 2, Phase 3
46 Analgesics Phase 2, Phase 3
47 Anesthetics Phase 3
48 Gastrointestinal Agents Phase 2, Phase 3
49 Anti-Arrhythmia Agents Phase 3
50 Anticonvulsants Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 A National Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh (Prolift) Unknown status NCT00771225 Phase 4
2 Postoperative Pain After Propofol Sevoflurane Anaesthesia: a Prospective, Randomized, Single-blinded Trial Completed NCT01437462 Phase 4 Sevoflurane;Propofol
3 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
4 Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation (IVF)/ IntraCytoplasmic Sperm Injection (ICSI): Pharmacokinetics and the Impact on the Endometrium, the Microbiota of the Genital Tract and the Peripheral Immunology. Double Blind Crossover Study. Recruiting NCT03677336 Phase 4 Dydrogesterone Oral Tablet;Micronized progesterone;Placebo Dydrogesterone oral tablet;Placebo Micronized progesterone
5 Efficacity of Hypnosis Versus Premedication for the Management of Perioperative Anxiety in Gynecological Surgery Not yet recruiting NCT03327506 Phase 4 Alprazolam 0.5 mg
6 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study Unknown status NCT02097446 Phase 3
7 Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) for Intraperitoneal Adhesion in Patient With Gynecological Surgery, a Multicenter Single-blinded, Randomized Study Unknown status NCT03007654 Phase 3
8 LIdocaine Gel Versus Plain Lubricating Gel for Pain Reduction During Transrectal Sonography (LIPS) Completed NCT02567838 Phase 3 Lidocaine gel;Placebo
9 Pulmonary Recruitment Maneuver to Reduce Postlaparoscopic Shoulder Pain: Randomized Controlled Trial Completed NCT02596425 Phase 3
10 Novel Topical Therapies for the Treatment of Genital Pain Completed NCT02099006 Phase 2, Phase 3 Amitriptyline;Baclofen;Ketoprofen;Ketamine;Loperamide;Gabapentin;placebo
11 A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer Recruiting NCT03555422 Phase 3 Selinexor;Placebo
12 Chlorhexidine Gluconate Versus Povidone Iodine for Vaginal Surgical Preparation for Urogynecological Procedures Recruiting NCT04048356 Phase 3 Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
13 Effect of Elastic Abdominal Binder on Pain and Functional Recovery After Open Abdominal Surgery for Benign Gynecologic Conditions: a Randomized Controlled Trial Recruiting NCT03820115 Phase 3
14 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
15 LSH vs. TLH, A Randomized Single Blind Trial Withdrawn NCT00734812 Phase 3
16 Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX Unknown status NCT02338505 Phase 2
17 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
18 Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium Completed NCT00456924 Phase 2 VA2914
19 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
20 A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women Completed NCT00365716 Phase 2
21 A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3) Completed NCT02139267 Phase 2
22 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
23 Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers Completed NCT01523678 Phase 2 Filgrastim;Paclitaxel;Carboplatin
24 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
25 The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus Recruiting NCT03656666 Phase 2 Apremilast;Placebo
26 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
27 Preoperative Warm-up in Gynecologic Surgery Using a Virtual Reality Simulator. Completed NCT01712607 Phase 1
28 To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Intrauterine Surgery in Patient With Gynecological Disease, a Multicenter, Randomized, Double- Blinded Study Unknown status NCT02957500
29 Validation of an ERAS Protocol in Gynecological Surgery: an Italian Randomized Controlled Trial Unknown status NCT03347409
30 Comparison Between Exclusive Surgical Training Versus Virtual Reality Plus Traditional Training in Surgical Skills of Residents of Obstetrics and Gynecology Unknown status NCT03395821
31 A Prospective Randomized Clinical Trial for Comparing Postoperative Pain Following COX-2 and Prostanoids Expression in Women Who Underwent Laparoscopic Surgery for Female Genital Disease Unknown status NCT03391570 COX-2 inhibitor;Placebo Oral Tablet
32 Comparison of Volume- and Pressure- Controlled Ventilation With Laryngeal Mask Airway Guardian in Obese Patients Undergoing Laparoscopic Gynecologic Surgery—A Perspective, Randomized, Blind Trial Unknown status NCT02097628
33 Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study Unknown status NCT03016039
34 Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates Unknown status NCT01271400
35 Prospective Validation and Comparison of Subjective Assessment, the International Ovarian Tumor Analysis (IOTA) ADNEX Model, Logistic Regression Model LR2, Simple Rules and the Risk of Malignancy Index (RMI) for Discrimination Between Benign and Malignant Adnexal Masses in the Hands of Ultrasound Examiners With Different Levels of Experience Unknown status NCT02847832
36 Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging Unknown status NCT02836275
37 Measuring the Mechanism of Incontinence With Urethral Pressure Reflectometry, Before and After Genital Prolapse Surgery Unknown status NCT02050568
38 An Evaluation of the Safety and TechnIcal Feasibility Of the NelLa Women's Care Line for Female Gynecological ExaminaTions and Procedures (VIOLET) Completed NCT03123367
39 A Randomized Study Comparing Four Different Postoperative Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy Completed NCT01526668
40 Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects Completed NCT02747641
41 Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers Completed NCT02233283
42 Eeva Continued Access Study. Completed NCT01617993
43 Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche Completed NCT01523652
44 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
45 A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse Completed NCT02642835
46 Phase 4 Study of Optimal Dose of Haloperidol Completed NCT01639599 Dexamethasone iv injection;Dexamethasone, haloperidol;Dexamethasone, haloperidol
47 Impact of Football Matches on the Emergency Admissions of a Level III Maternity During EURO 2016 Completed NCT03984617
48 Ultrasonic Versus Monopolar Energy-based Surgical Device in Colpotomy During Total Laparoscopic Hysterectomy in Terms of Surgical Smoke and Lateral Thermal Damage: a Randomized Controlled Trial (ULMOST Trial) Completed NCT02729272
49 Study on the Antiaging Effect of Chinese Herb Drink Completed NCT02634242
50 Combined Electroacupuncture and Auricular Acupuncture for Postoperative Pain After Abdominal Surgery for Gynecological Diseases: A Randomized Sham-controlled Trial Completed NCT02851186

Search NIH Clinical Center for Female Reproductive System Disease

Cochrane evidence based reviews: genital diseases, female

Genetic Tests for Female Reproductive System Disease

Anatomical Context for Female Reproductive System Disease

MalaCards organs/tissues related to Female Reproductive System Disease:

40
Ovary, Cervix, Uterus, Bone, Breast, Thyroid, Skin

Publications for Female Reproductive System Disease

Articles related to Female Reproductive System Disease:

# Title Authors PMID Year
1
[Analysis on reproductive health status and influencing factors of female workers of pharmaceutical industry in Gansu province]. 61
22356709 2011

Variations for Female Reproductive System Disease

Expression for Female Reproductive System Disease

Search GEO for disease gene expression data for Female Reproductive System Disease.

Pathways for Female Reproductive System Disease

Pathways related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.96 MIR9-1 MIR34A MIR31 MIR30A MIR27A MIR214
2 10.07 MIR199A1 MIR145

GO Terms for Female Reproductive System Disease

Cellular components related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR31 MIR30A MIR27A MIR21 MIR199A1 MIR182

Biological processes related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.03 MIR34A MIR30A MIR21 MIR182 MIR146A
2 negative regulation of gene expression GO:0010629 9.93 MIR27A MIR214 MIR21 MIR17 MIR146A
3 gene silencing by miRNA GO:0035195 9.91 MIR141 MIR143 MIR145 MIR146A MIR17 MIR182
4 negative regulation of cell migration GO:0030336 9.9 MIR9-1 MIR34A MIR214 MIR21
5 cellular response to hypoxia GO:0071456 9.86 MIR34A MIR214 MIR17 MIR146A
6 positive regulation of angiogenesis GO:0045766 9.85 MIR143 MIR199A1 MIR21 MIR30A MIR31
7 negative regulation of protein kinase B signaling GO:0051898 9.8 MIR34A MIR146A MIR145
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.78 MIR196A1 MIR193A MIR146A
9 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.76 MIR34A MIR214 MIR182
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.75 MIR31 MIR27A MIR146A
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.74 MIR21 MIR199A1 MIR145
12 positive regulation of blood vessel endothelial cell migration GO:0043536 9.71 MIR143 MIR200A MIR30A MIR31
13 negative regulation of angiogenesis GO:0016525 9.7 MIR143 MIR145 MIR146A MIR193A MIR21 MIR214
14 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR17 MIR199A1 MIR27A
15 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MIR17 MIR21 MIR214 MIR27A
16 positive regulation of cellular senescence GO:2000774 9.66 MIR34A MIR146A
17 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.66 MIR21 MIR17
18 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.65 MIR34A MIR17
19 negative regulation of cardiac muscle hypertrophy GO:0010614 9.65 MIR21 MIR145
20 regulation of smooth muscle contraction GO:0006940 9.65 MIR145 MIR143
21 positive regulation of connective tissue replacement GO:1905205 9.65 MIR199A1 MIR214 MIR34A
22 positive regulation of metalloendopeptidase activity GO:1904685 9.64 MIR21 MIR17
23 angiotensin-activated signaling pathway GO:0038166 9.64 MIR145 MIR143
24 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.62 MIR21 MIR17
25 negative regulation of lamellipodium assembly GO:0010593 9.62 MIR214 MIR196A1
26 aorta smooth muscle tissue morphogenesis GO:0060414 9.61 MIR145 MIR143
27 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR17 MIR199A1 MIR214
28 regulation of phenotypic switching GO:1900239 9.59 MIR145 MIR143
29 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR182 MIR21 MIR214 MIR34A
30 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.55 MIR17 MIR143
31 negative regulation of vascular smooth muscle cell dedifferentiation GO:1905175 9.52 MIR182 MIR145
32 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.51 MIR145 MIR143
33 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.5 MIR141 MIR146A MIR31
34 miRNA mediated inhibition of translation GO:0035278 9.28 MIR145 MIR146A MIR17 MIR182 MIR21 MIR27A

Molecular functions related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.58 MIR9-1 MIR518D MIR34A MIR31 MIR30A MIR27A

Sources for Female Reproductive System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....